​

Funding Round

Series B - ArriVent Biopharma

Series B - ArriVent Biopharma

Investment Firm

Overview

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Announced Date

Dec 29, 2022

Closed on Date

Mar 27, 2023

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

General Catalyst

General Catalyst

General Catalyst is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Sofinnova Investments

Sofinnova Investments

Sofinnova Investments is a early_stage_venture and late_stage_venture and post_ipo and venture firm.

Participant Investors

10

Investor Name
Participant InvestorOrbiMed
Participant InvestorSofinnova Investments
Participant InvestorHBM Partners
Participant InvestorLilly Asia Ventures
Participant InvestorGeneral Catalyst

Round Details and Background

ArriVent Biopharma raised $155000000 on 2022-12-29 in Series B

ArriVent develops pharmaceutical products to cure presently untreatable cancer.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 30, 2021
Series A - ArriVent Biopharma
6-81.0M
Feb 15, 2022
Series A - ArriVent Biopharma
6-69.0M
Dec 29, 2022
Series B - ArriVent Biopharma
17-155.0M

Recent Activity

There is no recent news or activity for this profile.